Abstract:Damage to DNA is caused by ionizing radiation, genotoxic chemicals or collapsed replication forks. When DNA is damaged or cells fail to respond, a mutation that is associated with breast or ovarian cancer may occur. Mammalian cells control and stabilize the genome using a cell cycle checkpoint to prevent damage to DNA or to repair damaged DNA. Checkpoint kinase 2 (Chk2) is one of the important kinases, which strongly affects DNA-damage and plays an important role in the response to the breakage of DNA double-strands and related lesions. Therefore, this study concerns Chk2. Its purpose is to find potential inhibitors using the pharmacophore hypotheses (PhModels) and virtual screening techniques. PhModels can identify inhibitors with high biological activities and virtual screening techniques are used to screen the database of the National Cancer Institute (NCI) to retrieve compounds that exhibit all of the pharmacophoric features of potential inhibitors with high interaction energy. Ten PhModels were generated using the HypoGen best algorithm. The established PhModel, Hypo01, was evaluated by performing a cost function analysis of its correlation coefficient (r), root mean square deviation (RMSD), cost difference, and configuration cost, with the values 0.955, 1.28, 192.51, and 16.07, respectively. The result of Fischer’s cross-validation test for the Hypo01 model yielded a 95% confidence level, and the correlation coefficient of the testing set (rtest) had a best value of 0.81. The potential inhibitors were then chosen from the NCI database by Hypo01 model screening and molecular docking using the cdocker docking program. Finally, the selected compounds exhibited the identified pharmacophoric features and had a high interaction energy between the ligand and the receptor. Eighty-three potential inhibitors for Chk2 are retrieved for further study.

Drug Discovery Targeting Chk1 and Chk2 Kinases.

Targeting the checkpoint kinases: chemosensitization versus chemoprotection

Targeting DNA checkpoint kinases in cancer therapy.

Targeting DNA repair pathways: a novel approach to reduce cancer therapeutic resistance.

Recent Advances in Cancer Therapy Targeting Proteins Involved in DNA Double-Strand Break Repair

DNA damage checkpoint kinases in cancer

Design checkpoint kinase 2 inhibitors by pharmacophore modeling and virtual screening techniques.

The ATM-Chk2 and ATR-Chk1 pathways in DNA damage signaling and cancer.

Functions and Inhibitors of CHK1 in Cancer Therapy

Design, Synthesis and Biological Evaluation of Thienopyridinones As Chk1 Inhibitors

Targeting the DNA Damage Response for Cancer Therapy by Inhibiting the Kinase Wee1

Perspectives on the Combination of Radiotherapy and Targeted Therapy with DNA Repair Inhibitors in the Treatment of Pancreatic Cancer.

Mammalian Chk2 is a Downstream Effector of the ATM-dependent DNA Damage Checkpoint Pathway

DNA-PKcs: A Multi-Faceted Player in DNA Damage Response

Targeting Mouse Double Minute 2: Current Concepts in DNA Damage Repair and Therapeutic Approaches in Cancer.

The DNA Damage Effector Chk1 Kinase Regulates Cdc14B Nucleolar Shuttling During Cell Cycle Progression

DNA-PK as an Emerging Therapeutic Target in Cancer

DNA-Dependent Protein Kinase Catalytic Subunit (DNA-PKcs): Beyond the DNA Double-Strand Break Repair

Radiation-induced Phosphorylation of Chk1 at S345 is Associated with p53-dependent Cell Cycle Arrest Pathways

Guarding against digestive-system cancers: Unveiling the role of Chk2 as a potential therapeutic target

Molecular Pathways: Emergence of Protein Kinase CK2 (CSNK2) as a Potential Target to Inhibit Survival and DNA Damage Response and Repair Pathways in Cancer Cells